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Aims
To determine ten-year failure rates following 36 mm metal-on-metal (MoM) Pinnacle total 
hip arthroplasty (THA), and identify predictors of failure.
Patients and Methods
We retrospectively assessed a single-centre cohort of 569 primary 36 mm MoM Pinnacle 
THAs (all Corail stems) followed up since 2012 according to Medicines and Healthcare 
Products Regulation Agency recommendations. All-cause failure rates (all-cause revision, 
and non-revised cross-sectional imaging failures) were calculated, with predictors for failure 
identified using multivariable Cox regression.
Results
Failure occurred in 97 hips (17.0%). The ten-year cumulative failure rate was 27.1% (95% 
confidence interval (CI) 21.6 to 33.7). Primary implantation from 2006 onwards (hazard ratio 
(HR) 4.30; 95% CI 1.82 to 10.1; p = 0.001) and bilateral MoM hip arthroplasty (HR 1.59; 95% 
CI 1.03 to 2.46; p = 0.037) predicted failure. The effect of implantation year on failure varied 
over time. From four years onwards following surgery, hips implanted since 2006 had 
significantly higher failure rates (eight years 28.3%; 95% CI 23.1 to 34.5) compared with hips 
implanted before 2006 (eight years 6.3%; 95% CI 2.4 to 15.8) (HR 15.2; 95% CI 2.11 to 110.4; 
p = 0.007).
Conclusion
We observed that 36 mm MoM Pinnacle THAs have an unacceptably high ten-year failure 
rate, especially if implanted from 2006 onwards or in bilateral MoM hip patients. Our 
findings regarding implantation year and failure support recent concerns about the device 
manufacturing process. We recommend all patients undergoing implantation since 2006 
and those with bilateral MoM hips undergo regular investigation, regardless of symptoms.
Cite this article: Bone Joint J 2017;99-B:592–600.
Adverse reactions to metal debris (ARMD)
have contributed to the high failure rates
observed with stemmed metal-on-metal total
hip arthroplasties (MoM THAs).1-5 These
implants are no longer used and patients with
these devices currently require regular surveil-
lance.6-8 The Medical and Healthcare Products
Regulatory Agency (MHRA) recommends that
all patients with stemmed MoM THAs and a
36 mm or larger diameter femoral head
undergo annual review, which includes meas-
urement of blood metal ions with or without
cross-sectional imaging.6
The 36 mm MoM Pinnacle THA system
(DePuy, Leeds, United Kingdom) was commonly
implanted worldwide.4,9-11 Although this design
has not performed as poorly as other MoM
THAs, registries have still observed high ten-year
cumulative revision rates of up to 14.6%.4,11 A
number of large single-centre cohort studies
examining the 36 mm MoM Pinnacle THA sys-
tem have also confirmed these high failure
rates.10,12-14 Langton et al10 recently identified
new predictors of revision in 489 MoM Pinna-
cle THAs with a 36 mm bearing, namely
implantation from 2006 onwards, bilateral
MoM hip implants, and small Pinnacle liners.
Furthermore, explant analysis at their national
retrieval centre demonstrated that a number of
Pinnacle implants were manufactured out of
their intended specification.10 However, a sub-
sequent review of the 36 mm MoM Pinnacle
THA system within the National Joint Registry
(NJR) for England and Wales did not observe a
higher revision rate for the identified batch
numbers compared with others.15
Given the potential implications of the find-
ings reported by Langton et al10 on follow-up
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regimens for patients with 36 mm MoM Pinnacle THAs, it
is important for the newly identified risk factors to be
assessed in external cohorts. We previously reported the
medium-term outcomes of the 36 mm MoM Pinnacle THA
system at our specialist centre,12 which represents the sec-
ond largest study of this particular device.9,10,13,14 The fail-
ure rate at eight years (11.1%) was unacceptably high in
our initial study with many revisions performed for
ARMD.12 However, risk factors for implant failure were
not formally assessed in our previous study or in most other
reports.9,12,14,16
We aimed to determine the cumulative all-cause failure
rate at ten years following implantation of the 36 mm
MoM Pinnacle THA system and identify risk factors
for failure, with specific focus on the newly identified
predictors.10
Patients and Methods
This retrospective single-centre cohort study included
patients treated with a primary MoM Pinnacle THA
implanted between 2004 and 2010. This study was regis-
tered with the hospital board of our institution; however,
ethical approval was not required as patients were assessed
according to published regulatory authority guidance.6 All
patients received a cementless Corail femoral stem (DePuy).
For the present study only hips receiving a 36 mm diameter
Articul/eze femoral head (DePuy) were included (14 hips
with 28 mm diameter femoral heads excluded). There were
569 primary 36 mm MoM Pinnacle THAs (504 patients)
eligible for study inclusion (Table I). These patients have
been reported on previously, with information regarding
the implants used, surgical procedure, patient follow-up,
and blood metal ion analysis described in detail.12,17
Patient follow-up. In 2012, the institution’s routine follow-
up of patients with the 36 mm MoM Pinnacle THA system
was adapted according to recommendations from the
MHRA.6 All patients were recalled for clinical assessment,
which was performed by a combination of senior (consult-
ant) hip surgeons and specialist arthroplasty advanced
nurse practitioners in dedicated MoM hip clinics. This clin-
ical assessment included history, examination, anteroposte-
rior pelvic radiographs, blood metal ion sampling,17 and
completion of the Oxford Hip Score (OHS) question-
naire.18 The OHS is scored on a scale of 0 to 48 points (0,
worst possible joint; 48, healthy joint).19
All symptomatic hips underwent cross-sectional imag-
ing, with asymptomatic hips undergoing cross-sectional
imaging if blood metal ion concentrations were above 7 μg/l
(MHRA upper-limit).6 The institution’s cross-sectional
imaging protocol has previously been described.17,20 Briefly,
Table I. Demographic details of the patient cohort
Covariate 569 hips in 504 patients, n (%)
Gender Female 331 (58.2)
Male 238 (41.8)
Age at primary (yrs) Mean (range) 60.4 (19.8 to 88.0)
Laterality Unilateral MoM hips 425 (74.7)
Bilateral MoM hips* 144 (25.3)
Primary (yr) 2004 24 (4.2)
2005 55 (9.7)
2006 63 (11.1)
2007 125 (22.0)
2008 175 (30.8)
2009 113 (19.9)
2010 14 (2.5)
Pre-2006 79 (13.9)
2006 onwards 490 (86.1)
Diagnosis Primary osteoarthritis 524 (92.1)
Other 45 (7.9)
Surgeon grade Consultant 550 (96.7)
Other 19 (3.3)
Surgeon volume ≥ 50 cases (3 surgeons) 431 (75.8)
< 50 cases (21 surgeons) 138 (24.3)
Surgical approach Posterior 531 (93.3)
Anterolateral 38 (6.7)
Liner size (mm) Median (range) 54 (50 to 66)
50 to 52 273 (48.0)
54 134 (23.6)
56 to 66 162 (28.5)
Femoral head offset Median (range) 5.0 (-2.0 to 12.0)
*includes 65 bilateral patients (130 hips) with both implants in each patient included in this study, and 14 further
patients (14 hips) with unilateral 36 mm MoM Pinnacle total hip arthroplasties included in this study with these
patients also having another MoM hip design (36 mm or larger diameter femoral head) on the contralateral side
MoM, metal-on-metal 
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this protocol recommends ultrasound for symptomatic
patients and metal artifact reduction sequence magnetic res-
onance imaging (MARS-MRI) for asymptomatic patients. If
MARS-MRI was contraindicated then ultrasound was per-
formed. Patients were considered to be symptomatic if when
questioned they complained of ipsilateral groin or thigh
pain, and/or had experienced episodes of hip squeaking,
clicking, grating, locking, clunking, other noises, or instabil-
ity (and/or these could be elicited during clinical examina-
tion). Although no specific OHS threshold was used to
distinguish symptomatic patients from asymptomatic indi-
viduals, symptomatic patients typically had an OHS of less
than 34 of 48 (which represents a fair or poor score; median
OHS in symptomatic patients was 30 of 48).19
All subsequent patient follow-up was dependent on the
outcome of the initial assessment. Patients with normal
investigations were reviewed annually. Patients with abnor-
mal investigations not undergoing revision were seen more
regularly and underwent repeat investigations, typically
every three to six months. Revision surgery was recom-
mended based on the overall results of the clinical assess-
ment, with no single investigation used to make decisions
regarding revision. Revision surgery for ARMD was per-
formed in certain asymptomatic patients based on abnor-
mal investigations.
Exposure variables and outcomes of interest. Data for this
study were extracted from the institution’s prospectively
maintained clinical database. Exposure covariates of inter-
est recorded in this database included patient demographics
(gender, age, MoM hip laterality and hip diagnosis), and
details related to the primary surgery (year of surgery, sur-
geon grade and volume, approach, acetabular liner size and
femoral head offset).
The study outcome of interest was all-cause failure. The
definition for failure included revision surgery performed
for any indication, and non-revised hips with cross-
sectional imaging evidence of ARMD. Patients were con-
sidered to have imaging evidence of ARMD if they had a
pathological effusion or pseudotumour as previously
described.21-23 Pathological effusions were diagnosed when
the depth of fluid exceeded 15 mm at the anterior joint line
on ultrasound22 and the patient had raised blood cobalt
concentrations (above 3.57 μg/l as recently described).17 A
pseudotumour was defined as a cystic, solid or mixed mass
in continuity with the hip joint but extending beyond the
confines of the anatomical joint.22,23 Lesions meeting these
criteria were diagnosed as pseudotumours regardless of the
wall thickness or blood metal ion concentrations. Hips with
imaging evidence of ARMD remained under regular sur-
veillance due to clinician and/or patient preference. This
included circumstances where patients had decided against
revision surgery whilst asymptomatic, or where revision
surgery had been recommended but patients were unfit to
undergo further surgery.
Revision surgery was defined as removal or exchange of
any component implanted at the primary surgery, including
isolated femoral head and acetabular liner exchanges. In all
revised cases, the database and hospital records were
reviewed to determine the cause of failure. This included
review of the pre-revision investigations, the revision oper-
ation report, and the results of the microbiological and
histopathological analyses performed on intra-operative
samples. Hips were considered revised for ARMD if there
was intra-operative evidence of pseudotumour, metallosis,
synovitis, tissue damage and/or necrosis, combined with
histopathological confirmation of ARMD.23-27 If revision
surgery had been performed at another centre, the institu-
tion was contacted to obtain the relevant data. All arthro-
plasty surgeons have an individual NJR profile which
tracks the outcomes of any THAs they have performed,
even when further procedures are undertaken by other indi-
viduals at another centre.28 Revisions were identified as
having occurred elsewhere when the patient had informed
us of such procedures, or if additional revisions had been
identified from the primary surgeon’s individual NJR pro-
file. All failures up until October 2016 were included in this
study. No primary 36 mm MoM Pinnacle THAs were
awaiting revision surgery at the time of writing.
Statistical analysis. This was performed using Stata Version
14.2 (Stata Corp., College Station, Texas). The significance
level for all analyses was a p-value < 0.05, with 95% confi-
dence intervals (CI) also used. Cumulative implant failure
rates following primary 36 mm MoM Pinnacle THA were
estimated using the Kaplan-Meier method. Hips that did
not fail were censored on the date of last clinical follow-up,
or on the date of death.
Cox proportional hazards models (univariable and
multivariable) were used to assess the effects of the predic-
tor variables on time to failure. For continuous predictors,
fractional polynomial regression modelling was used to
assess the assumption of linearity with outcome, with data
grouped if the assumption was not satisfied. Proportional
hazards assumptions for each predictor were assessed using
Schoenfeld’s residuals.29 If these assumptions were not sat-
isfied, the hazard ratios (HR) were examined in various
follow-up time groups, with breaks placed at the points of
divergence from proportionality. Likelihood ratio tests
were used to assess evidence of two-way interactions
between gender and other predictors, including acetabular
liner size. The final multivariable model was developed
using stepwise backward selection methods. In this auto-
mated process all potential predictors are initially included
in the model with p-values for removing (p ≥ 0.20) and
including (p < 0.10) predictors in the final multivariable
model set. The analytical software subsequently compares
different statistical models and sequentially removes any
variables that do not significantly affect the model fit until
the final model with the best fit is identified. As a sensitivity
analysis, the models were also repeated with all-cause revi-
sion surgery used as the endpoint.
As the effect of year on primary 36 mm MoM Pinnacle
THA implantation (pre-2006 versus 2006 onwards) on
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failure rate was being assessed, further analyses were per-
formed to more accurately examine these relationships.
Previous work highlighted potential variations in the 36
mm MoM Pinnacle THA system manufacturing process
from 2006 onwards.10 Given that 2006 was the transition
year for this potential variation, Cox regression analyses
were repeated with all hips implanted in 2006 excluded.
Furthermore, the follow-up time from primary implanta-
tion between groups was different with the pre-2006
implantation group having longer follow-up than the 2006
onwards group. To control for this follow-up variability the
Cox regression analyses were repeated in a subgroup of
hips. This subgroup included all non-failed hips with a min-
imum of eight years follow-up (with these hips all censored
as not failing at eight years) and all failed hips. For this par-
ticular analysis, all hips failing before eight years were cen-
sored as failures but any hips failing after eight years were
censored at eight years as not failing. Follow-up was trun-
cated at eight years because after this time there were fewer
hips at risk in the 2006 onwards group.
Results
Failures occurred in 97 hips (17.0%) at a mean time of 6.0
years (0.01 to 12.2) from primary arthroplasty. These fail-
ures consisted of 75 all-cause revisions and 22 additional
ARMD imaging failures under surveillance. ARMD was
the most common indication for failure (n = 72; 74.2% of
all failures) and for revision surgery (n = 50; 66.7% of all
revisions). Non-ARMD revision indications were aseptic
loosening (n = 8; 10.7%), infection (n = 6; 8.0%), disloca-
tion (n = 5; 6.7%), and other (n = 6; 8.0%). Of the 22
ARMD imaging failures, 20 hips had large cystic (n = 18) or
mixed (n = 2) pseudotumours, with 15 of these patients
having blood cobalt concentrations above the 3.57 μg/l
threshold.17 Pseudotumour volumes ranged from 30 cm3 to
192 cm3. The remaining two ARMD imaging failures were
pathological effusions. These were cystic collections (vol-
umes between 25 cm3 and 30 cm3), with blood cobalt con-
centrations of 8.1 μg/l and 9.2 μg/l respectively.
There were 23 non-failing hips (4.0%) that died at a
mean time of 2.8 years (0.04 to 7.2) from surgery. The
remaining 449 hips that did not fail or die were followed up
for a mean time of 8.0 years (1.0 to 12.0). The median
(interquartile range (IQR)) whole blood cobalt and chro-
mium concentrations in these patients at latest follow-up
were 2.36 μg/l (IQR 0.83 to 4.30) and 1.46 μg/l (IQR 0.88
to 2.44), respectively. The median post-operative OHS was
43 of 48 (IQR 33 to 48).
Failure rates. The cumulative ten-year failure rate following
primary 36 mm MoM Pinnacle THA was 27.1% (95% CI
21.6 to 33.7; 67 hips remained at risk at ten years) (Fig. 1).
The ten-year rate for revision surgery only (i.e. excluding
the ARMD imaging failures) was 20.3% (95% CI 15.7%
to 26.1%).
Risk factors for failure. Multivariable analysis identified
two predictors of failure: bilateral MoM hip arthroplasty
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Fig. 1
Graph showing cumulative all-cause failure rate following 36 mm primary metal-on-metal Pinnacle total hip
arthroplasty at up to ten years. Shaded area represents the respective upper and lower limits of the 95% con-
fidence intervals (CIs). Risk table indicates the number of hips at risk at two year intervals, with the correspond-
ing number in brackets detailing the number of failed hips during each two-year interval. Seven failures
occurred after ten-years follow-up and therefore are not included in the risk table.
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(HR 1.59, 95% CI 1.03 to 2.46; p = 0.037), and primary
hip implantation from 2006 onwards (HR 4.30, 95% CI
1.82 to 10.1; p = 0.001) (Table II). The ten-year failure rate
was 35.8% (95% CI 24.4% to 50.4%) in bilateral MoM
hip patients (all sequential hip implantations) compared
with 24.2% (95% CI 18.2% to 31.7%) in unilateral
patients (Fig. 2). 
After excluding hips implanted in 2006 (n = 63), primary
implantation from 2007 onwards remained a predictor of
failure compared with hips implanted before 2006 (HR
4.55, 95% CI 1.84 to 11.2; p = 0.001). Further analysis
regarding year of implantation was performed on 304 hips
(72 failures). This demonstrated that the effect of year of
primary implantation on failure rates varied over time.
Year of implantation did not affect failure rates within four
years of arthroplasty (HR 1.60, 95% CI 0.47 to 5.44;
p = 0.450), with four-year failure rates of 7.5% (95% CI
4.8% to 11.6%) and 4.7% (95% CI 1.5% to 13.8%) for
hips implanted from 2006 onwards and before 2006
respectively (Fig. 3). Between four years and eight years
from primary surgery, hips implanted from 2006 onwards
had a significantly higher failure rate (at eight years 28.3%,
Table II. Univariable and multivariable Cox regression models for identifying risk factors for all-cause failure
Covariate Univariable hazard ratio (95% CI) p-value Multivariable hazard ratio (95% CI) p-value
Gender
Female vs male 1.61 (1.03 to 2.50) 0.036* 1.49 (0.94 to 2.37) 0.092
Age at primary (per yr) 1.02 (0.99 to 1.04) 0.142 1.02 (0.99 to 1.05) 0.085
Laterality
Bilateral vs unilateral 1.60 (1.04 to 2.45) 0.031* 1.59 (1.03 to 2.46) 0.037*
Yr of primary
2006 onwards vs pre-2006 4.88 (2.09 to 11.4) < 0.001* 4.30 (1.82 to 10.1) 0.001*
Diagnosis
Primary osteoarthritis vs other 1.69 (0.69 to 4.17) 0.252 † †
Surgeon grade
Consultant vs other 0.44 (0.18 to 1.09) 0.075 0.55 (0.22 to 1.37) 0.199
Surgeon volume
≥ 50 cases vs < 50 cases 0.74 (0.47 to 1.17) 0.196 † †
Surgical approach
Posterior vs anterolateral 0.53 (0.25 to 1.17) 0.115 0.55 (0.24 to 1.24) 0.148
Liner size 
50 mm to 52 mm 1.00 (reference group) 1.00 (reference group)
54 mm 0.62 (0.36 to 1.06) 0.083 0.66 (0.38 to 1.12) 0.125
56 mm to 66 mm 0.65 (0.39 to 1.08) 0.095 ‡ ‡
Femoral head offset 
per +3.5 increase 0.80 (0.63 to 1.02) 0.078 0.81 (0.62 to 1.07) 0.138
*statistically significant differences (p < 0.05)
†covariate was not eligible for inclusion in the final multivariable model 
‡specific subgroup did not meet inclusion criteria for final multivariable model (p > 0.200)
CI, confidence interval
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Fig. 2
Graph showing cumulative all-cause failure rates following 36 mm pri-
mary metal-on-metal Pinnacle total hip arthroplasty at up to ten-years by
implant laterality; 95% confidence intervals have been included in the
main text, but are omitted from the figure for clarity.
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Fig. 3
Graph showing cumulative all-cause failure rates following 36 mm pri-
mary metal-on-metal Pinnacle total hip arthroplasty at up to eight years by
year of implantation. Shaded area represents the respective upper and
lower limits of the 95% confidence intervals (CIs). Model based on a sub-
group of 304 hips (72 all-cause failures) with 232 hips at risk at eight years.
RISK FACTORS FOR FAILURE OF THE 36 MM METAL-ON-METAL PINNACLE TOTAL HIP ARTHROPLASTY SYSTEM 597
VOL. 99-B, No. 5, MAY 2017
95% CI 23.1% to 34.5%) compared with hips implanted
before 2006 (at eight years 6.3%, 95% CI 2.4% to 15.8%)
(HR 15.2, 95% CI 2.11 to 110.4; p = 0.007).
Small liner size did not predict failure. Likelihood ratio
testing demonstrated a borderline significant interaction
between liner size and gender (p = 0.0493). The effect of
liner size on failure rates was further examined in men and
women separately, which confirmed that liner size did not
predict failure in either gender.
Risk factors for revision surgery were also examined.
The results from the multivariable analysis were the same
as for all-cause failure, with bilateral MoM hip arthro-
plasty (HR 2.02, 95% CI 1.25 to 3.25; p = 0.004), and pri-
mary hip implantation from 2006 onwards (HR 2.64, 95%
CI 1.12 to 6.20; p = 0.026) identified as predictors of revi-
sion.
Discussion
The 36 mm MoM Pinnacle THA system was one of the
most commonly implanted MoM THAs worldwide.4,9-11
Recently, Langton et al10 identified new risk factors for
implant failure, which raised serious questions regarding
the device manufacturing process since 2006. The clinical
implications of the concerns raised by Langton et al10
regarding potential errors in the manufacturing tolerances
are significant; therefore it is important for other institu-
tions, such as ours, to publish their data. The present study
represents one of the largest non-registry cohorts of 36 mm
MoM Pinnacle THA patients, and has the longest follow-
up period.9,10,13,14 High ten-year failure rates were
observed with the 36 mm MoM Pinnacle THA system, with
ARMD representing the most common indication for fail-
ure. However, the greatest risk of device failure occurred in
hips implanted from 2006 onwards, and in bilateral MoM
hip arthroplasty patients. Our findings therefore support
the newly identified risk factors for 36 mm MoM Pinnacle
THA failure.10
The unacceptably high failure rates of stemmed MoM
THAs are undisputed, with these devices no longer
implanted worldwide.1-4 Whilst some MoM THAs had
very high short-term failure rates, such as the ASR XL
(DePuy), the 36 mm MoM Pinnacle THA system did not
perform as poorly according to registry data.4,11 However,
registries have recognised limitations, including the poten-
tial to under-report revisions and the inability to account
for non-revised imaging failures.30,31 We observed high
rates of failure (27.1%) and revision surgery (20.3%) at ten
years following primary 36 mm MoM Pinnacle THA. Our
revision rate was comparable with recent studies from
Langton et al10 (n = 489) and Lainiala et al13 (n = 430) who
reported rates of up to 16.4% at nine years. However, we
considered it important to include non-revised patients
with imaging evidence of ARMD as failures. This more
accurately estimates the scale of the problem, given that the
threshold for performing revision may differ between sur-
geons, and patients with failing implants may be unfit or
unwilling to undergo further surgery. Indeed, all of the non-
revised patients with imaging failures identified in our pre-
vious report have now undergone revision surgery.12
It is suspected that surveillance bias introduced from regu-
lar patient follow-up6,8 has contributed to the high rates of
failure and revision reported by this and other studies for the
36 mm MoM Pinnacle THA system.10,12-14 However, the fail-
ure rate continues to increase steadily up to ten years (Fig. 1)
rather than plateau as one may expect following early revi-
sion of poorly performing implants. Perhaps more concern-
ing are the recent observations that in MoM hip resurfacing
patients, failure rates continue to increase up to 15 years from
implantation.32 Stemmed MoM THAs have higher failure
rates compared with hip resurfacings, even when bearing sur-
faces are identical.2,4,11,33 Therefore we suspect many more
MoM THAs will require revision in the second decade fol-
lowing implantation. This itself is likely to be problematic
given that the outcomes reported following MoM hip revi-
sion surgery for ARMD have also been poor.34,35
The most important predictor of failure in our cohort
was primary implantation from 2006 onwards. However,
hips implanted from 2006 onwards only had a significantly
higher failure rate between four years and eight years from
primary surgery (Fig. 3), with most failures due to ARMD.
This reflects the time at which ARMD failures can be
expected to occur.10,36 Langton et al10 similarly identified
an increased risk of failure in 36 mm MoM Pinnacle THAs
implanted from 2006 onwards. Furthermore, the findings
from their national implant retrieval centre, which receives
many failed prostheses from numerous institutions, demon-
strated that 36 mm MoM Pinnacle THAs manufactured
from 2006 onwards were increasingly likely to have lower
clearance values than intended by the manufacturer.10 Low
clearance between the femoral head and acetabular liner
can lead to edge loading, excessive bearing wear, and ulti-
mately implant failure.37 Furthermore, low clearance may
contribute to higher friction at the bearing surface and/or
taper junction, which can also result in increased wear and
implant failure.38,39
In light of the findings from two large clinical cohorts
comprising over 1000 36 mm MoM Pinnacle THA systems
and the results of the retrieval analysis on failed implants
from a wide geographical area,10 we conclude that the
potential variations in manufacturing tolerances are
unlikely to be confined to a specific batch of implants and/
or region of the country. Our findings regarding implanta-
tion year and failure therefore support recent concerns
about the 36 mm MoM Pinnacle THA system manufactur-
ing process since 2006.10 Although large registry cohorts
would help support these new observations, registries have
recognised limitations.30,31 In addition, the high failure
rates associated with MoM hip arthroplasties were identi-
fied by others5,40 some time before registries detected the
problem.11,41 Therefore, there may be a delay before regis-
tries identify a higher failure rate in 36 mm MoM Pinnacle
THAs implanted since 2006.
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Some regulatory authorities consider patients with bilat-
eral MoM hip arthroplasties to be at increased risk of fail-
ure,8,42 given that these patients can develop bilateral
ARMD.43-45 Bilateral failures seem to occur in patients
undergoing sequential hip implantation, with suggestion
that a delayed type IV immune reaction is responsible.43-45
We observed patients with bilateral MoM hip arthroplast-
ies to be at high risk of implant failure, which confirms
recent findings in another 36 mm MoM Pinnacle THA
cohort10 but is contrary to that reported in large hip resur-
facing cohorts.32 Bilateral MoM THAs may have a higher
risk of failure compared with bilateral hip resurfacings
given recent observations that metal debris generated from
taper junctions can be more immunogenic than that from
bearing surfaces.46 Further research is therefore needed
regarding the pathogenesis of failure in bilateral MoM hip
arthroplasties. However, we consider 36 mm MoM Pinna-
cle THA patients with bilateral MoM hips at high risk of
failure and therefore recommend these patients undergo
regular surveillance.
In this study, small acetabular liner size did not predict
failure, both in the whole cohort and when subdivided by
gender. Although Langton et al10 recently reported small
liner size as a predictor of failure when assessed as a cate-
gorical variable, small liner size was not a significant pre-
dictor in their all-cause revision model. Assessing liner size
in MoM THAs is difficult given it is closely related to gen-
der, much like the complex relationship observed between
gender and femoral head size in hip resurfacing.32 Assess-
ment in 36 mm MoM Pinnacle THAs is further compli-
cated by there being nine different liner sizes available
(50 mm to 66 mm), with the smallest size not introduced
until 2008 (hence liner size was grouped in this study).
Although we do not feel that 36 mm MoM Pinnacle THA
patients require risk stratification for clinical surveillance
based on liner size, it is recommended that future studies
assessing this implant explore the relationship between
liner size and implant failure.
Given that we have now validated the risk factors for
failure of the 36 mm MoM Pinnacle THA system initially
reported by Langton et al,10 it is important that the many
patients worldwide with these implants in situ are managed
appropriately. Current MHRA follow-up recommenda-
tions suggest that asymptomatic patients with non-ASR
stemmed MoM THRs and a 36 mm or larger diameter fem-
oral head only require cross-sectional imaging if blood
metal ion concentrations are above 7 μg/l and rising on
repeat testing.6 We suggest this follow-up guidance should
be modified so that all 36 mm MoM Pinnacle THAs
implanted since 2006 and those with bilateral MoM hips
should also undergo cross-sectional imaging, regardless of
symptoms. However, this additional follow-up is likely to
be very costly and resource intensive,47 given that most
patients with these devices are asymptomatic10,12,13 and
most of these prostheses were implanted from 2006
onwards.4,11 
The main study limitation is that hips revised at this insti-
tution did not undergo explant analysis. Therefore, unlike
in the recent study by Langton et al,10 we cannot confirm
whether or not the specific Pinnacle implants removed were
manufactured outside of their intended specification.
Although attempts were made to identify all revisions,
including using NJR surgeon data, it is possible some hips
were revised elsewhere and not reported to the NJR; there-
fore, our failure rates represent the best-case scenario. The
formal radiographic analysis from the initial study12 was
not updated here; therefore it is acknowledged that some
non-revised patients may have radiological evidence of
implant failure which may eventually require revision.
Despite assessing a large cohort at extended follow-up, it is
recognised this represents a selected population in a specific
geographical area. Although registries have limitations,30,31
analysis of a large unselected registry cohort would comple-
ment the single-centre cohort studies performed by our-
selves and others.10 A further limitation is the lack of a
control group of patients with other MoM THA designs.
Such a comparator group would allow a more accurate
assessment of the extent of surveillance bias on implant fail-
ure rates in more recent years.6-8 Finally, although our sur-
vival analysis was robust, there is a potential for residual
confounding.
In conclusion, this large cohort study has demonstrated
that the 36 mm MoM Pinnacle THA system has an unac-
ceptably high ten-year failure rate. The failure rate was
especially high in hips implanted from 2006 onwards and
in bilateral MoM hip arthroplasty patients. Our findings
regarding year of implantation and failure rates support
recent serious concerns about previously unrecognised
changes in the device manufacturing process.10 We recom-
mend that all patients with 36 mm MoM Pinnacle THA
systems implanted since 2006 and those with bilateral
MoM hips undergo regular investigation, including blood
metal ions and cross-sectional imaging, regardless of
symptoms.
Take home message:
- An unacceptably high ten-year failure rate was observed in
36 mm MoM Pinnacle THA systems, especially in those
implanted from 2006 onwards, and in bilateral MoM hip patients. 
- All patients with these devices implanted since 2006, and those with
bilateral MoM hips should undergo regular investigation with blood metal
ions and cross-sectional imaging, regardless of symptoms.
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